Neoplasm Clinical Trials

10 recruiting

Neoplasm Trials at a Glance

1,562 actively recruiting trials for neoplasm are listed on ClinicalTrialsFinder across 6 cities in 78 countries. The largest study group is Not Applicable with 425 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running neoplasm studies include M.D. Anderson Cancer Center, Mayo Clinic, and National Cancer Institute (NCI).

Treatments under study

About Neoplasm Clinical Trials

Looking for clinical trials for Neoplasm? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 1,562 trials

Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Bladder CancerKidney CancerRenal Cancer+2 more
National Cancer Institute (NCI)5,950 enrolled1 locationNCT00026884
Recruiting
Phase 1Phase 2

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

CholangiocarcinomaBile Duct NeoplasmBiliary Tract Malignancy
National Cancer Institute (NCI)31 enrolled1 locationNCT04645160
Recruiting
Phase 2

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Lung Neuroendocrine NeoplasmAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine Tumor+9 more
National Cancer Institute (NCI)70 enrolled29 locationsNCT04665739
Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

NeoplasmsHealthy VolunteersHematologic Neoplasms
National Heart, Lung, and Blood Institute (NHLBI)6,000 enrolled1 locationNCT00071045
Recruiting
Phase 1

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

Solid TumorsNeoplasms
National Cancer Institute (NCI)65 enrolled1 locationNCT03366116
Recruiting
Not Applicable

The Vanguard Study: Testing a New Way to Screen for Cancer

Breast CarcinomaOvarian CarcinomaBladder Carcinoma+8 more
National Cancer Institute (NCI)24,000 enrolled37 locationsNCT06995898
Recruiting

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

Gastric CancerGastric NeoplasmGastrointestinal Stromal Tumor (GIST)+2 more
National Cancer Institute (NCI)400 enrolled1 locationNCT04557969
Recruiting

Clinical and Genetic Studies of Li-Fraumeni Syndrome

NeoplasmsLi-Fraumeni SyndromeTp53 Mutations
National Cancer Institute (NCI)5,000 enrolled2 locationsNCT01443468
Recruiting

Tumor Related Epilepsy

CancerEpilepsyBrain Neoplasm
National Institute of Neurological Disorders and Stroke (NINDS)100 enrolled1 locationNCT02639325
Recruiting
Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled346 locationsNCT05564390
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting

Epidemiological and Molecular Colorectal Cancer Registry

Colorectal Neoplasms
Hospital Italiano de Buenos Aires2,100 enrolled1 locationNCT02781337
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 2

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

Malignant Solid NeoplasmMalignant Female Reproductive System NeoplasmRecurrent Malignant Solid Neoplasm+1 more
National Cancer Institute (NCI)70 enrolled185 locationsNCT06126276
Recruiting
Phase 2

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm+1 more
National Cancer Institute (NCI)335 enrolled220 locationsNCT05554406
Recruiting
Not Applicable

Questionnaire on Congenital Cancer Signs Through Self-Assessment

Pediatric CancerHereditary Cancer SyndromesCancer Predisposition Syndromes+1 more
Insel Gruppe AG, University Hospital Bern205 enrolled1 locationNCT07378423
Recruiting
Phase 3

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled174 locationsNCT07060807
Recruiting
Phase 3

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Ovarian CancerOvarian Neoplasms
Merck Sharp & Dohme LLC900 enrolled28 locationsNCT07318558
Recruiting
Phase 3

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Breast Neoplasms
BioNTech SE558 enrolled83 locationsNCT07173751